Skip to content
Precision for Medicine
Contact Us
Category Hero Image

Execute Clinical Trial Feasibility with Precision

Optimize your study's initiation through precise country and site selection, powered by actionable insights.
At Precision, our feasibility process is more than just a preliminary step; it's a critical foundation for the success of your clinical trial. By focusing on strategic site selection and in-depth insights gathering, we ensure your study starts with a significant advantage. 
iStock-876250496

Plan for success with Site Feasibility

Site feasibility is the cornerstone of clinical trial planning, acting as the bridge between groundbreaking research and its successful execution. Understanding the pivotal role of site feasibility ensures a solid foundation for any clinical study. It's not merely about identifying potential sites but about strategic alignment with the trial's objectives, patient populations, and operational capacities. This proactive approach to site selection, grounded in data-driven insights and comprehensive evaluations, mitigates risks and sets the stage for successful patient enrollment and study outcomes.

Roughly 80% of clinical trials fail to meet original enrollment timelines, and about one-third of Phase III study terminations are due to enrollment difficulties. Additionally, 15% to 20% of sites never enroll a single patient.

Given these statistics, it's evident that conducting a comprehensive feasibility study is essential for avoiding common pitfalls like poor enrollment and sites that never enroll.  Precision's feasibility team employs multiple methods to ensure a sponsor's needs are met, tailoring our approach to each unique trial. This adaptability, combined with a deep understanding of the intricacies of clinical trials, allows Precision to navigate complex requirements and ensure trials are set up for success from the start.

Precision's Clinical Trial Feasibility process overview

Step 1

Initial Planning
  • Understand study objectives
  • Identify target countries/sites
  • Develop feasibility questionnaire
  • Augment site list with Precision/external data
  • Site list finalized for feasibility start

Step 2

Data Collection & Analysis
  • Distribute questionnaires
  • Pursue sites for response
  • Collect sites responses
  • Evaluate sites performance
  • Prepare feasibility report
  • Review report with client
  • Filter out low-potential sites

Step 3

Recruitment Modeling
  • Develop enrollment scenarios
  • Estimate recruitment timelines
  • Project patient numbers
  • Adjust site requirements
  • Plan for contingencies
  • Present models to clients

Step 4

Site Selection & Verification
  • Confirm top-performing sites
  • Schedule pre-study visits
  • Verify site infrastructure
  • Assess staff expertise
  • Determine recruitment potential
  • Finalize site list for activation
  • Finalize back-up site list

Step 5

Performance Monitoring
  • Regular progress check-ins
  • Address emerging issues
  • Adjust recruitment plans
  • Activate backup sites
  • Ensure timeline adherence
  • Provide ongoing support

Precision’s strategic approach to clinical trial feasibility

Our approach to site feasibility is both comprehensive and meticulous. By integrating broad data analysis with site-specific insights, we ensure each trial starts on the best possible footing. Our process begins with understanding study objectives and identifying optimal countries and sites, followed by developing and distributing targeted feasibility questionnaires. We then analyze site responses and performance, preparing detailed feasibility reports for client review. Through recruitment modeling, we project patient numbers and timelines, allowing for adjustments and contingency planning. Site selection is confirmed through pre-study visits and infrastructure verification, with backup sites identified for risk mitigation. Continuous performance monitoring ensures adherence to timelines and proactive issue resolution, backed by ongoing support. This strategic and detailed approach enables our sponsors to navigate trial complexities with confidence, ensuring successful study execution.

Our site feasibility services can be executed during pre-study phases or integrated into full study start-up processes. This flexibility allows us to adapt to each sponsor's unique requirements, providing tailored support that aligns with their specific clinical trial needs.

Insights from Precision’s experts

Stay ahead with the latest insights from Precision’s team of experts. Discover valuable perspectives, updates, and strategies to navigate early and late phase development. 

Explore our blog
Read: Case Study: Delivering an Early-Phase Autoimmune Trial Across Regions Case Study: Delivering an Early-Phase Autoimmune Trial Across Regions

Clinical Trials - Early Phase Research - Autoimmune

Case Study: Delivering an Early-Phase Autoimmune Trial Across Regions

|
    has third author: false, (SizeLimitingPyMap: {main={hs_id=214928090133, hs_child_table_id=0, hs_updated_at=1781285625399, hs_published_at=1781630742683, description=Deborah Spencer is a Senior Director of Project Management at Precision for Medicine with over 25 years of experience in clinical research. She specialises in leading global clinical trials across multiple phases, with deep expertise in complex study delivery. Deborah provides strategic oversight of programmes, leads high-performing teams, and partners closely with sponsors to ensure successful execution and regulatory readiness., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Deborah%20Spencer.jpg',altText='Deborah Spencer',fileId=214838919278}, lastname=Spencer, hs_initial_published_at=1781285742914, hs_created_by_user_id=26433386, hs_created_at=1781285562019, hs_is_edited=false, hs_deleted_at=0, name=Deborah, job=Senior Director, Project Management, slug=deborah-spencer, hs_updated_by_user_id=26433386}, second={hs_id=214928170660, hs_child_table_id=0, hs_updated_at=1781285676367, hs_published_at=1781630742683, description=Anthea Gates is a Project Director with approximately 30 years of drug development and medical device industry expertise across all phases, over a variety of indications including breast, lung cancer, solid tumors and lymphoma, cutaneous T-cell lymphoma, malignant melanoma, squamous cell carcinoma, rare haematologic disease, autoimmune rheumatology, osteoarthritis, ocular burns, liver cirrhosis, myopia and pre-eclampsia. Committed to delivering quality and passionate about building positive relationships with clients and study teams to promote cohesive business practices and ensure the successful management of projects from start to finish. Anthea holds a proven track record in effective leadership of cross-functional teams across programs of studies, to the accomplishment of operational excellence., avatar=Image{width=372,height=546,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/profile.jpg',altText='profile',fileId=214846873938}, lastname=Gates, hs_initial_published_at=1781285742914, hs_created_by_user_id=26433386, hs_created_at=1781285639221, hs_is_edited=false, hs_deleted_at=0, name=Anthea, job=Project Director, slug=anthea-gates, hs_updated_by_user_id=26433386}, third={hs_id=214928090141, hs_child_table_id=0, hs_updated_at=1781285738567, hs_published_at=1781630742683, description=Claire Delaville is a Senior Project Manager at Precision for Medicine. She brings 18 years of experience across preclinical and clinical research, including more than a decade leading Phase I to IV studies in oncology, rare diseases, and immunology, with direct experience in first-in-human and multicenter oncology trials. Claire is responsible for maintaining study quality through inspection readiness, corrective action planning, and proactive risk mitigation. She also oversees study budgets and vendor performance to support coordinated delivery across functions, drawing on a scientific foundation that includes a PhD in Neurosciences and Neuropharmacology. Based in Paris, France, Claire aligns scientific insight with operational execution to support successful trial outcomes., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Claire%20Delaville.jpg',altText='Claire Delaville',fileId=214838927033}, lastname=Delaville, hs_initial_published_at=1781285742914, hs_created_by_user_id=26433386, hs_created_at=1781285678112, hs_is_edited=false, hs_deleted_at=0, name=Claire, job=Senior Project Manager, slug=claire-delaville, hs_updated_by_user_id=26433386}})
  • Deborah S. avatar Anthea G. avatar Claire D. avatar

  • Deborah S.

    Anthea G.

    Claire D.
Discover
Read: Early‑Phase Autoimmune Drug Development: Trial Design, Biomarkers and Statistical Strategies Early‑Phase Autoimmune Drug Development: Trial Design, Biomarkers and Statistical Strategies

Clinical Trials

Early‑Phase Autoimmune Drug Development: Trial Design, Biomarkers and Statistical Strategies

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=213698206365, hs_child_table_id=0, hs_updated_at=1780680681226, hs_published_at=1781630742683, description=Rui F. Duarte‑Lopes is a senior biostatistics leader with over 31 years of international experience across biopharmaceutical, biotechnology, and CRO sectors. He provides strategic statistical oversight, ensuring rigorous, high‑quality, and decision‑focused delivery aligned with sponsor and regulatory expectations. He has more than 12 years of CRO experience supporting Phase I–IV clinical trials and has held roles including Lead Statistician, Project Lead, and Senior Manager. His therapeutic experience includes oncology and autoimmune diseases, notably lupus erythematosus, Crohn's disease and rheumatoid arthritis. Specializing in oncology over the past six years, Rui focuses on advanced solid tumors and early‑phase studies, contributing to study design, interim analyses, and data‑driven decision frameworks., avatar=Image{width=1200,height=1200,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/Rui%20F%20Duarte-Lopes.jpg',altText='Rui F Duarte-Lopes',fileId=213695319705}, lastname=Duarte-Lopes, hs_initial_published_at=1779886328878, hs_created_by_user_id=26433386, hs_created_at=1779886165792, hs_is_edited=false, hs_deleted_at=0, name=Rui F, job=Senior Manager, Biostatistics, slug=rui-f-duarte-lopes, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Rui F Duarte-Lopes avatar

    Rui F Duarte-Lopes
Discover
Read: China’s New Drug Regulatory Framework Positions the Country as a Global Hub for Innovative Medicine Launches China’s New Drug Regulatory Framework Positions the Country as a Global Hub for Innovative Medicine Launches

Clinical Trials

China’s New Drug Regulatory Framework Positions the Country as a Global Hub for Innovative Medicine Launches

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=209983237513, hs_child_table_id=0, hs_updated_at=1774533604788, hs_published_at=1781630742683, description=Calvin Niu received his BD in pharmaceuticals from Lanzhou University. He has brought over 22 years of drug development and regulatory experience in pharmaceutical companies and CROs. Calvin’s regulatory expertise covers regulatory agency engagements and all types of regulatory submissions throughout product development and post market life cycles in oncology, immunology, ophthalmology, clinical nutrition, cardiovascular, gastroenterology, women’s health, CNS, rare disease, etc. , avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Calvin%20Niu.png',altText='Calvin Niu',fileId=209991702802}, lastname=Niu, hs_initial_published_at=1774533614867, hs_created_by_user_id=51739740, hs_created_at=1774531720533, hs_is_edited=false, hs_deleted_at=0, name=Calvin, job=Director, Regulatory Affairs, China, slug=calvin-niu, hs_updated_by_user_id=26433386}, second={}, third={}})
  • Calvin Niu avatar

    Calvin Niu
Discover

Advance therapeutic breakthroughs with Precision

Explore the breadth of our expertise in therapeutics and modalities, as we lead your novel treatments in Oncology, Rare Diseases and beyond, from the groundbreaking idea to clinical realization.

Oncology Explore Rare diseases Explore Autoimmune Explore Gene Therapy Explore Cell Therapy Explore

Clinical trial excellence: Precision in all phases

With people across 70+ countries, our team provides comprehensive clinical trial services that streamline and accelerate drug development at a global scale

  • Explore
    iStock-1635827172

    Early Phase Excellence

    Embark on the critical first steps of clinical discovery with our expertly managed early phase trials, where meticulous attention meets innovative strategy.
    Explore

    Early Phase Excellence

    Embark on the critical first steps of clinical discovery with our expertly managed early phase trials, where meticulous attention meets innovative strategy.
    Explore
  • Explore
    blood-lab-tech

    Late Phase Success

    Discover the path to market with our Late Phase Development expertise – delivering precision, scale, and efficiency for your clinical journey.
    Explore

    Late Phase Success

    Discover the path to market with our Late Phase Development expertise – delivering precision, scale, and efficiency for your clinical journey.
    Explore

Specialized capabilities in every stage of clinical development

Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to accelerate speed to market. Precision can customize and converge our capabilities to meet your program's unique needs—driving efficiency, agility, and success from start to finish.

  • Discover Explore
    clinical-trial-support

    Global CRO
    Services

    Award-winning CRO with deep oncology and rare disease expertise

    Explore
  • Discover Explore
    specialty-lab-services

    Global Laboratory
    Services

    Exceptional translational and biomarker sciences with global central lab services

    Explore
Loading...